Not Only for the Risk of Bone Fracture

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2015 May 12

PMID 25959644

Authors

Masafumi Fukagawa

Affiliations

Soon will be listed here.

References

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama J . Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013; 17(3):247-88. DOI: 10.1111/1744-9987.12058. View

Kazama J, Matsuo K, Iwasaki Y, Fukagawa M . Chronic kidney disease and bone metabolism. J Bone Miner Metab. 2015; 33(3):245-52. DOI: 10.1007/s00774-014-0639-x. View

Kanis J, Johnell O, Oden A, Johansson H, McCloskey E . FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4):385-97. PMC: 2267485. DOI: 10.1007/s00198-007-0543-5. View

Naylor K, Leslie W, Hodsman A, Rush D, Garg A . FRAX predicts fracture risk in kidney transplant recipients. Transplantation. 2014; 97(9):940-5. DOI: 10.1097/01.TP.0000438200.84154.1a. View

Jamal S, West S, Nickolas T . The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int. 2013; 25(1):71-6. DOI: 10.1007/s00198-013-2524-1. View

Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B . FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014; 6(6):744-59. PMC: 4203353. DOI: 10.1002/emmm.201303716. View

Wakasugi M, Kazama J, Taniguchi M, Wada A, Iseki K, Tsubakihara Y . Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab. 2013; 31(3):315-21. DOI: 10.1007/s00774-012-0411-z. View

Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A . Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int. 2008; 19(4):429-35. PMC: 2267486. DOI: 10.1007/s00198-007-0544-4. View

Hayashi T, Joki N, Tanaka Y, Iwasaki M, Kubo S, Asakawa T . The FRAX ® as a predictor of mortality in Japanese incident hemodialysis patients: an observational, follow-up study. J Bone Miner Metab. 2015; 33(6):674-83. DOI: 10.1007/s00774-014-0631-5. View

10.

Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M . Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int. 2007; 71(8):738-43. DOI: 10.1038/sj.ki.5002097. View

11.

Coe L, Madathil S, Casu C, Lanske B, Rivella S, Sitara D . FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014; 289(14):9795-810. PMC: 3975025. DOI: 10.1074/jbc.M113.527150. View

12.

Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M . Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant. 2005; 20(9):1904-11. DOI: 10.1093/ndt/gfh876. View

13.

Komaba H, Kakuta T, Fukagawa M . Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011; 15(6):797-809. DOI: 10.1007/s10157-011-0502-5. View

14.

Jadoul M, Albert J, Akiba T, Akizawa T, Arab L, Bragg-Gresham J . Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006; 70(7):1358-66. DOI: 10.1038/sj.ki.5001754. View

15.

Kazama J, Iwasaki Y, Fukagawa M . Uremic osteoporosis. Kidney Int Suppl (2011). 2014; 3(5):446-450. PMC: 4089591. DOI: 10.1038/kisup.2013.93. View

16.

Fukagawa M, Hamada Y, Nakanishi S, Tanaka M . The kidney and bone metabolism: Nephrologists' point of view. J Bone Miner Metab. 2006; 24(6):434-8. DOI: 10.1007/s00774-006-0719-7. View

17.

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K . Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11):1945-53. DOI: 10.1038/sj.ki.5000414. View

18.

Tanaka H, Iwasaki Y, Yamato H, Mori Y, Komaba H, Watanabe H . p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone. 2013; 56(2):347-54. DOI: 10.1016/j.bone.2013.07.002. View

19.

Faul C, Amaral A, Oskouei B, Hu M, Sloan A, Isakova T . FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121(11):4393-408. PMC: 3204831. DOI: 10.1172/JCI46122. View

20.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y . FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3):429-35. DOI: 10.1359/JBMR.0301264. View